Driehaus Capital Management Reduces $7M in Spyre Therapeutics, Inc. ($SYRE)
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Driehaus Capital Management trimmed its position in Spyre Therapeutics, Inc. ($SYRE) by 3.18% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,790,785 shares of Spyre Therapeutics, Inc. after selling 91,635 shares during the quarter. Driehaus Capital Management's holdings in Spyre Therapeutics, Inc. were worth $225.47 million as of its most recent filing.
Spyre Therapeutics, Inc. Stock Down 10.6%
Shares of Spyre Therapeutics, Inc. ($SYRE) traded around $80.79 on Saturday, down 10.6% for the day.
Spyre Therapeutics, Inc. Earnings
Analysts Set New Price Targets
About Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Get Spyre Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $SYRE, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.